About

Coriolis Pharma is a global contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offerings include liquid and lyophilized freeze-dried drug formulation development from early stage to market approval and beyond, lyophilization freeze-drying process development, and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service offering. More than 725 clients – from start-ups to big pharma – already rely on Coriolis’s scientific expertise. For each project, our highly skilled scientists develop customized study designs that align with our customers’ drug development strategies. About Coriolis Pharma Research Gmbh Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines. We provide high-quality services for liquid and lyophilized drug products from early stage to commercialization and beyond. Manufacturing support and contract analytical services under R&D and GMP complete our service portfolio. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. About Coriolis Pharma Research Gmbh Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines. We provide high-quality services for liquid and lyophilized drug products from early stage to commercialization and beyond. Manufacturing support and contract analytical services under R&D and GMP complete our service portfolio. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. Coriolis Pharma is a globally operating, science‑driven contract research and development organization (CRDO) specializing in drug product development, formulation, lyophilization technologies, and advanced analytics for biopharmaceuticals. Founded in 2008 and with laboraties in Europe and the U.S., the company supports clients from early development to commercialization, offering both R&D and GMP-compliant analytical services across a broad range of biological modalities. As a premier partner for biopharmaceutical innovation, Coriolis Pharma provides expertise in developing liquid and lyophilized drug products, optimizing stability for proteins, peptides, nucleic acids, vaccines, gene and cell therapy products, and virus(-like) particles up to biosafety level S2. Its interdisciplinary team, supported by an expert scientific advisory board, delivers cutting‑edge, tailor-made solutions designed to accelerate and de-risk drug development programs throughout the entire product lifecycle. Coriolis Pharma’s service portfolio includes comprehensive analytical method development, qualification, and validation, ensuring robust regulatory support for biopharmaceutical pipelines. Its commitment to scientific excellence, innovation, and independent operation makes the company a trusted partner for biotechnology firms and pharmaceutical developers worldwide. Meet Coriolis Pharma at the BIO Convention to learn how their integrated development, analytical, and manufacturing services can help advance your biotherapeutic programs faster, safer, and more efficiently.